In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Enliven Therapeutics Inc (NASDAQ: ELVN) closed the day trading at $21.7 down -0.32% from the previous closing price of $21.77. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 0.88 million shares were traded. ELVN stock price reached its highest trading level at $22.45 during the session, while it also had its lowest trading level at $21.55.
Ratios:
For a better understanding of ELVN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.95 and its Current Ratio is at 32.95. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42. On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Lyssikatos Joseph P sold 12,500 shares for $22.33 per share. The transaction valued at 279,155 led to the insider holds 902,688 shares of the business.
Kintz Samuel sold 12,500 shares of ELVN for $272,739 on Nov 17 ’25. The PRESIDENT AND CEO now owns 890,392 shares after completing the transaction at $21.82 per share. On Nov 19 ’25, another insider, Lyssikatos Joseph P, who serves as the Officer of the company, bought 12,500 shares for $22.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1287836800 and an Enterprise Value of 810761792.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.36, which has changed by -0.1432507 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $25.96, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is 5.47%, while the 200-Day Moving Average is calculated to be 8.22%.
Shares Statistics:
Over the past 3-months, ELVN traded about 543.64K shares per day on average, while over the past 10 days, ELVN traded about 501450 shares per day. A total of 59.26M shares are outstanding, with a floating share count of 43.24M. Insiders hold about 27.14% of the company’s shares, while institutions hold 77.97% stake in the company. Shares short for ELVN as of 1763078400 were 7794126 with a Short Ratio of 14.32, compared to 1760486400 on 6422840. Therefore, it implies a Short% of Shares Outstanding of 7794126 and a Short% of Float of 18.69.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2 analysts currently analyzing and rating the stock of Enliven Therapeutics Inc (ELVN).The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.36 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.96 and -$1.96 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
